Article
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
BMJ open - 3 Mar 2022
Berger Frédérique, Marce Margaux, Delaloge Suzette, Hardy-Bessard Anne-Claire, Bachelot Thomas, Bièche Ivan, Pradines Anne, De La Motte Rouge Thibault, Canon Jean-Luc, André Fabrice, Arnould Laurent, Clatot Florian, Lemonnier Jérôme, Marques Sandrine, Bidard François-Clement
Abstract excerpt
INTRODUCTION: The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer. However, most patients receiving this combination will ultimately progress and require further therapies.Several studies have demonstrated that the onset of a ESR1 gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.